Next Article in Journal
Cannabinoids and Viral Infections
Next Article in Special Issue
Phospholipase D2 Enhances Epidermal Growth Factor-Induced Akt Activation in EL4 Lymphoma Cells
Previous Article in Journal
Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation
Previous Article in Special Issue
Opportunities to Target Specific Contractile Abnormalities with Smooth Muscle Protein Kinase Inhibitors
Pharmaceuticals 2010, 3(6), 1842-1872; doi:10.3390/ph3061842

Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome

1,* , 2,* , 1, 1 and 2,*
1 School of Chemistry, Main Building, Cardiff University, Park Place, Cardiff, CF10 3AT, UK 2 Department of Pathology, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK
* Authors to whom correspondence should be addressed.
Received: 31 March 2010 / Revised: 13 May 2010 / Accepted: 26 May 2010 / Published: 4 June 2010
(This article belongs to the Special Issue Protein Kinase Inhibitors)
View Full-Text   |   Download PDF [667 KB, uploaded 4 June 2010]   |   Browse Figures


Werner syndrome provides a convincing model for aspects of the normal ageing phenotype and may provide a suitable model for therapeutic interventions designed to combat the ageing process. Cultured primary fibroblast cells from Werner syndrome patients provide a powerful model system to study the link between replicative senescence in vitro and in vivo pathophysiology. Genome instability, together with an increased pro-oxidant state, and frequent replication fork stalling, all provide plausible triggers for intracellular stress in Werner syndrome cells, and implicates p38 MAPK signaling in their shortened replicative lifespan. A number of different p38 MAPK inhibitor chemotypes have been prepared rapidly and efficiently using microwave heating techniques for biological study in Werner syndrome cells, including SB203580, VX-745, RO3201195, UR-13756 and BIRB 796, and their selectivity and potency evaluated in this cellular context. Werner syndrome fibroblasts treated with a p38 MAPK inhibitor reveal an unexpected reversal of the accelerated ageing phenotype. Thus the study of p38 inhibition and its effect upon Werner pathophysiology is likely to provide new revelations into the biological mechanisms operating in cellular senescence and human ageing in the future.
Keywords: accelerated ageing; inflammation; microwave-assisted synthesis; p38 MAPK; progeroid syndrome; Werner syndrome accelerated ageing; inflammation; microwave-assisted synthesis; p38 MAPK; progeroid syndrome; Werner syndrome
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Bagley, M.C.; Davis, T.; Murziani, P.G.S.; Widdowson, C.S.; Kipling, D. Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome. Pharmaceuticals 2010, 3, 1842-1872.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert